SWK Holdings provides portfolio update

Originations: In November, SWK advanced $5.0M to existing borrower Journey Medical to help fund the company’s launch of Emrosi. In November, as part of a broader amendment SWK advanced $0.6M to existing borrower Biotricity. On amendment closing, SWK received 600,000 warrants to purchase Biotricity stock at $0.50 per share. In December, SWK closed an $8.0M senior secured term loan with Triple Ring Technologies, a leader in R&D and product co-development across the medtech, life sciences, sustainable agriculture, and environmental technology industries. In December, SWK advanced $2.5M to existing SWK borrower SKNV. In December, SWK closed a $25.7M expansion of its existing credit facility with Eton, which now totals $30.0M. On funding, SWK received 289,736 warrants to purchase Eton stock at $5.32 per share. In December, SWK advanced $2.5M to existing SWK borrower MedMinder. Repayments: In November, as a result of the sale of certain Exeevo assets to a third-party, SWK received a $3.4M net payment. In early January, SWK received an additional $0.7M net payment. SWK anticipates receiving a $0.5M payment during the first quarter of 2025 and is eligible for a three-year, annual earn-out based on the increase in gross profit. In November, SWK received a $13.0M payment from the Biolase bankruptcy estate. SWK anticipates receiving an additional payment from the estate in the first half of 2025. In December, SWK received a $1.9M payment from Trio Healthcare. SWK may receive an additional, small payment during 2025. In December, SWK received a $4.2M payment from Veru triggered by the sale of the FC2 Female Condom to a third-party. SWK has no remaining economics on the product. In January, Moleculight made a final payment to SWK totaling $12.2M, fully satisfying its outstanding obligation. SWK continues to hold Moleculight preferred equity, which is carried at no value on SWK’s balance sheet.